RH - week 3 Flashcards
(36 cards)
- Fiscal sustainability take-aways
- Sustainability of health care spending is (almost) never about affordability (in narrow sense). Issues are
o Efficiency
o Distribution of costs and benefits - Unsustainable government finances imply a funding gap that has to be filled by younger generations
o Financing defaults, like pay-as-you-go, put financial burden of health spending growth at younger/new generations - Although separate issues in theory, what is funded by the health system and how the system is funded are interrelated questions in practice
Types of fiscal rules
- Expenditure Rules
- Revenue Rules
- Debt Rules
- Balanced Budget Rules
Effects of fiscal rules on government spending
- Fiscal rules seem to have been successful in containing gov. spending
- Rules which embedded expenditure targets worked best
- Effect on transfers greater than on government consumption
- Endogeneity is a big issue: countries with greater intrinsic fiscal discipline might be more likely to set up fiscal rules
- Do health care budgets respond to fiscal pressure? Take-aways
- Health care spending is not unique and is affected by fiscal pressures and fiscal rules
- Fiscal rules might contribute to more predictable government spending and (moderately) contribute to medium-run health spending containment
- However,
o Risk of misallocation of resources across more/less protected sectors
o No guarantee of allocative efficiency (most value for money)
o One time savings, limited effects on long-term spending growth
- How do governments (try) to control health care spending?
Key policy challenges
- As medical care becomes more expensive, the tradeoff between equality and efficiency becomes even more difficult. How countries balance these three factors—the desire for equality, the goal of efficiency, and the increasing cost of medical care—will have major implications for medical-care systems for decades to come (Cutler, 2002)
- Many cost containment strategies hod the risk to turn into policies of cost-shifting (Stadhouders et al., 2016)
When is a technology cost-effective?
If the ICER is below the monetary threshold it is cost effective, if it is above it is not cost effective
absolute shortfall
disease - related health loss
proportional shortfall
(disease - related health loss) / remaining health expectations in absence of disease
fair innings
fair innings is the only severity approach that takes past health into account
two arguments in fair innings
- Equal innings argument:
* People who have not yet had their fair innings (i.e., a ‘normal’ life-span) are worse off than those who have (yet) had their fair innings
* QALY gains should be given weight >1 in economic evaluations - Sufficient innings argument:
* People who have had their fair innings are better off than those who have not (yet) had their fair innings
* QALY gains should be given weight <1 in economic evaluations
Why proportional shortfall?
Normative justification:
* Health technologies for more severely ill patients are more necessary
* Combines aspects of severity and fair innings approaches (past health disregarded)
* Balances concerns about discrimination based on age in reimbursement decisions (proportional shortfall is 1 in case of immediate death at all ages)
Equity weighting based on age
(Explicit) equity weighting based on age in economic evaluations is not allowed, but:
* Using QALYs in economic evaluations may prioritize younger patients (they have more potential QALYs to gain than older patients, so ICER more likely to be <vi)
* Prospective health and rule of rescue may prioritize older patients (they have less remaining QALYs than younger patients)
* Absolute shortfall may prioritize younger patients (they have more remaining QALYs left to lose than older patients)
* Proportional shortfall may prioritize older patients (they are more likely to lose a larger proportion of their remaining QALYs, e.g., in case of chronic illnesses).
Rationing in tax-funded healthcare system
Tax-funded healthcare acts are enforced by the government and and implemented by municipalities.
Government responsible for:
* Allocation of fixed budget to municipalities based on objective distribution key (supply-side rationing)
* Determining level of co-payments (demand-side rationing)
Municipalities (344 in March 2022) responsible for:
* (Timely) access to customized, high-quality care
* Early signalling of care needs
Rationing in insurance-based healthcare system
Insurance-based healthcare acts are enforced by the government and implemented by policymakers, health insurers and healthcare providers.
Long Term Care Act (Wlz):
* Mandatory income-based premium (≥ 15 years); fixed percentage (~10%) of income on a maximum gross income of ~€34,000
* Demand-side rationing:
o Access based on needs (re-) assessment by the Care Assessment Agency (CIZ) and availability of informal care
o Income-dependent copayment: accounts for differences in price sensitivity between SES groups and ensures access for lower income groups
Health Insurance Act (Zvw):
* Mandatory for everyone of >= 18 years
* Broad coverage of curative healthcare services
* Insurance companies obliged to accept anyone at same premium and contract competing care providers
* Healthcare allowance for lower income groups
Focus on demand-side rationing:
* Mandatory deductible of €385; voluntary deductible of +€500 against premium rebate of €240
* Demarcation of basic benefits package by National Health Care Institute (ZIN)
ZIN advises the Ministry of Health, Welfare and Sport on the demarcation of the basic benefits package on the basis of four decision criteria:
- necessity of care (proportional shortfall) and insurance
- effectiveness
- cost-effectiveness
- feasibility (e.g. budget impact)
Open system
Concerns specialist inpatient (pharmaceutical) care:
* Automatically included in basic benefits package if it meets the “medical science and practice” criterion
Since 2018:
* Expensive new pharmaceuticals are not automatically included in basic benefits package, but labelled “in transit” (in Dutch: “de sluis”) when:
o Costs are ≥ €50,000 per treatment per year and ≥ €10 million per year in total, or:
o Costs are ≥ €40 million per year in total, irrespective of costs per treatment
* Only included after price negotiations (ZIN advises Ministry of Health, Welfare and Sport on price reduction that is necessary to meet the cost-effectiveness criterion)
Closed system
Concerns outpatient (pharmaceutical) care:
* ZIN advises Minister of Health on inclusion in basic benefits package
Pharmaceuticals reimbursed if included in Drug Reimbursement System (GVS):
* Annex 1a –> Clustering of interchangeable pharmaceuticals
o Reimbursement limit
o Co-payment (max €250 per year) for pharmaceuticals that are above limit
* Annex 1b Unique pharmaceuticals
o Fully reimbursed
o Move to annex 1a when pharmaceuticals become interchangeable
* Annex 2 –> Unique or expensive pharmaceuticals (overlap annex 1a and 1b)
o Reimbursement if certain conditions are met (e.g., only reimbursed for specific subgroup)
Assessment phase
- Collecting, presenting and assessing information on the four decision criteria (necessity, effectiveness, cost-effectiveness, feasibility)
- (Independent) Scientific Advisory Board (WAR) assesses and advises ZIN on the quality and content of the available scientific evidence
- WAR meetings are private
Appraisal phase
- Naming and weighing all relevant arguments (see part 1, reasons for reimbursing technologies that are not cost-effective or vice versa)
- (Independent) Insured Package Advisory Committee (ACP) advises ZIN on decisions “that affect society”
- ACP meetings are public: stakeholders (e.g., patients and physicians) can respond in writing to ACP reports, but can also attend meetings and request speaking time (5 minutes)
Public involvement
Policymakers increasingly seek ways to (also) involve members of the public in reimbursement decisions, with the objective to:
* Actively involve the public in shaping new policies that affect their lives
* Better align outcomes and process of decision making with societal preferences
* Increase legitimacy of and societal support for decisions on rationing healthcare
berekening incremental costs
costs new treatment - costs standard care
berekening incremental QALY gain
effects new treatment - effects standard care
berekening incremental cost-effectiveness ratio
incremental costs / incremental QALY gain
Efficiency arguments
- Allocative efficiency
o Can we better spend additional health care euros on something else (either other gorvenment spending or private consumption)?
o Already central question in CEA (cost effectiveness analysis). Don’t really `need’ financial sustainability as a motivation… - Marginal costs of public funds (MCPF)
o Collective financing of health care comes at a cost: - Taxes distort individual decisions, e.g. to work